These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 24984026)
1. Anticancer activity of starch/poly[N-(2-hydroxypropyl)methacrylamide]: biomaterial film to treat skin cancer. Mohanraj S; Murugan D; Rengarajan A; Rajiv S Int J Biol Macromol; 2014 Sep; 70():116-23. PubMed ID: 24984026 [TBL] [Abstract][Full Text] [Related]
2. Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Zamai M; VandeVen M; Farao M; Gratton E; Ghiglieri A; Castelli MG; Fontana E; D'Argy R; Fiorino A; Pesenti E; Suarato A; Caiolfa VR Mol Cancer Ther; 2003 Jan; 2(1):29-40. PubMed ID: 12533670 [TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. Paranjpe PV; Chen Y; Kholodovych V; Welsh W; Stein S; Sinko PJ J Control Release; 2004 Nov; 100(2):275-92. PubMed ID: 15544875 [TBL] [Abstract][Full Text] [Related]
4. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967 [TBL] [Abstract][Full Text] [Related]
5. Reduction-responsive disassemblable core-cross-linked micelles based on poly(ethylene glycol)-b-poly(N-2-hydroxypropyl methacrylamide)-lipoic acid conjugates for triggered intracellular anticancer drug release. Wei R; Cheng L; Zheng M; Cheng R; Meng F; Deng C; Zhong Z Biomacromolecules; 2012 Aug; 13(8):2429-38. PubMed ID: 22746534 [TBL] [Abstract][Full Text] [Related]
6. Luminescent/magnetic hybrid nanoparticles with folate-conjugated peptide composites for tumor-targeted drug delivery. Shen JM; Guan XM; Liu XY; Lan JF; Cheng T; Zhang HX Bioconjug Chem; 2012 May; 23(5):1010-21. PubMed ID: 22486419 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug. Xu Z; Zheng W; Yin Z Arch Pharm (Weinheim); 2014 Apr; 347(4):240-6. PubMed ID: 24402828 [TBL] [Abstract][Full Text] [Related]
9. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. Li G; Li Y; Tang Y; Zhang Y; Zhang Y; Yin T; Xu H; Cai C; Tang X Int J Pharm; 2014 Aug; 471(1-2):234-44. PubMed ID: 24861941 [TBL] [Abstract][Full Text] [Related]
10. Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles. Kim C; Kim S; Oh WK; Choi M; Jang J Chemistry; 2012 Apr; 18(16):4902-8. PubMed ID: 22422377 [TBL] [Abstract][Full Text] [Related]
11. Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization. Ünal S; Aktaş Y; Benito JM; Bilensoy E Int J Pharm; 2020 Jun; 584():119468. PubMed ID: 32470483 [TBL] [Abstract][Full Text] [Related]
12. Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors. Kissel M; Peschke P; Subr V; Ulbrich K; Schuhmacher J; Debus J; Friedrich E PDA J Pharm Sci Technol; 2001; 55(3):191-201. PubMed ID: 11417110 [TBL] [Abstract][Full Text] [Related]
14. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Koo OM; Rubinstein I; Onyuksel H Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061 [TBL] [Abstract][Full Text] [Related]
15. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Acevedo-Morantes CY; Acevedo-Morantes MT; Suleiman-Rosado D; Ramírez-Vick JE Drug Deliv; 2013 Nov; 20(8):338-48. PubMed ID: 24024505 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Tong W; Wang L; D'Souza MJ Drug Dev Ind Pharm; 2003 Aug; 29(7):745-56. PubMed ID: 12906332 [TBL] [Abstract][Full Text] [Related]
18. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin. Tang XJ; Han M; Yang B; Shen YQ; He ZG; Xu DH; Gao JQ Int J Pharm; 2014 Dec; 477(1-2):536-45. PubMed ID: 25445532 [TBL] [Abstract][Full Text] [Related]
19. A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids. Li X; Kong X; Zhang J; Wang Y; Wang Y; Shi S; Guo G; Luo F; Zhao X; Wei Y; Qian Z J Pharm Sci; 2011 Jan; 100(1):232-41. PubMed ID: 20533555 [TBL] [Abstract][Full Text] [Related]
20. HepG2 Cell Resistance against Camptothecin from a Lysosomal Drug Delivery. Lee H; Uhm S; Shin JW; Jeon HM; Dongbang S; Jung HS; Na YC; Kang C; Kim JS Chem Asian J; 2015 Dec; 10(12):2695-700. PubMed ID: 26373261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]